Therapeutic Solutions to expand patient access to its JadiCell stem cell therapy for COVID

Jul. 18, 2022 11:00 AM ETTherapeutic Solutions International, Inc. (TSOI)By: Anuron Mitra, SA News Editor



  • Therapeutic Solutions International (OTCPK:TSOI) on Monday said it had been granted an emergency investigational new drug (IND) clearance by the U.S. FDA for expanded patient access to its JadiCell stem cell therapy for the treatment of COVID-19.
  • Shares of the micro-cap company gained 5% to $0.02 in Monday morning trading.
  • As per the emergency IND and a so-called "May Proceed Notification" from the FDA, TSOI can now provide the JadiCell stem cell therapy outside of its ongoing phase 3 clinical trial.
  • "With the increase in COVID-19 cases, as well as the anticipated deluge of COVID-19 ‘long hauler’ patients, it is imperative that we have mechanisms to provide these cells to patients who desperately need them, even if it is outside of the clinical trial," said TSOI chief medical officer James Veltmeyer.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.